Assessment of fracture risk

Current Osteoporosis Reports

Volumn 10, Issue 1, 2012, Pages 28-41

  Baim, Sanford ^a   Leslie, William D ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bone densitometry; Fracture; FRAX; Fracture risk; Osteoporosis

Indexed keywords

ARTICLE; BONE DENSITY; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE COST; HUMAN; MORBIDITY; MORTALITY; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; VALIDATION PROCESS; ALGORITHM; FALLING; HIP FRACTURE; PHOTON ABSORPTIOMETRY; RECURRENT DISEASE; REVIEW; STATISTICS;

ABSORPTIOMETRY, PHOTON; ACCIDENTAL FALLS; ALGORITHMS; BONE DENSITY; GUIDELINES AS TOPIC; HIP FRACTURES; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PRIMARY PREVENTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 84862262449     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-011-0093-9     Document Type: Article

References (82)

1. National Osteoporosis Foundation, Clinician's Guide to prevention and treatment of osteoporosis. 2008; available at http//nof.org/ professionals/NOF-clinicians-Guide pdf, accessed February 12, 2011. The NOF Clinician's Guide to prevention and treatment of osteoporosis serves as a basic reference for the evaluation and treatment of osteoporosis in the United States.
2. Kanis JA. 2007 WHO Technical Report, University of Sheffield, UK:66.
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726.
4. Gullber B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407.
5. Osteoporosis in the Workplace, 2002, www.IOF.org.
6. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;3:465-75. (Pubitemid 46797130)
7. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO; 1994.
8. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:17-1141.
9. Kanis JA, Johnell O, Oden A, Jonsson B, et al. Risk of hip fracture according to the World Health Organization criteria for osteoporosis and osteopenia. Bone. 2000;27:585-90.
10. World Health Organization Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO; 1998.
11. Marshall D, Johnell O, Edel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-59. (Pubitemid 26147662)
12. Cooper C, Aihie A. Osteoporosis: recent advances in pathogenesis and treatment. Q J Med. 1994;87:203-9. (Pubitemid 24113246)
13. Kanis JA, Borgstrom F, De laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581-9. (Pubitemid 40897454)
14. Lewiecki EM, Compston JE, Miller PD, et al. 2010 Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom. 2011;14:226-36.
15. Leslie WD, Tsang JF, Caetano PA, et al. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2007;92(1):77-81. (Pubitemid 46067512)
16. Wainwright SA, Marshall LM, Ensrud KE, et al. Study of Osteoporotic Fractures Research Group. Hip fractures in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787-93.
17. Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17(9):1404-9. (Pubitemid 44127328)
18. Sornay-Rendu E, Muoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture. The OFELY study. J Bone Miner Res. 2005;20(10):1813-19. (Pubitemid 41361882)
19. Alonso-Coello P, García-Franco AL, Guyatt G, et al. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ 2008;19;336(7636):126-9. (Pubitemid 351211963)
20. Lewiecki M. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom. 2010;13 (4):335-45.
21. Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment a randomized trial. Ann Intern Med. 2011;155:87-96.
22. Leslie WD. Absolute fracture risk reporting in clinical practice: a physician-centered survey. Osteoporos Int. 2008;19:459-63.
23. Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl2): S407-13.
24. Papaionnou A, Morin S, Cheung AM, et al. 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864-73.
25. Hamdy RC, Baim S, Broy SB. Algorithm for the management of osteoporosis. SMJ. 2010;103(10):1009-15.
26. FRAX® available at http://www.sheffield.ac.uk/FRAX/index.jsp, accessed on February 24, 2011.
27. World Health Organization. Assessment of osteoporosis at the primary health care level. WHO, Geneva, 2007; available at www.who.int/chp/topics/ rheumatic/en/index.html, accessed February, 23; 2011.
28. Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008;19:1431-44, available at http://www.garvan.org.au/bone-fracture-risk, accessed February 24, 2011.
29. Hippisley-Cox J, Copuland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009;339: b4229 available at http://www.qfracture.org/, accessed February 24, 2011.
30. Kanis JA on behalf of the World Health Organization Scientific Group a, Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. 2008, available at http://www.shef.ac.uk/FRAX/ index.htm, accessed February 24, 2011.
31. Oden A, Johansson H, McCloskey EV. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-97.
32. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-97.
33. Hans D, Kanis J, Baim S, et al. Joint official positions of the International Society for Clinical Densitometry (ISCD) and International Osteoporosis Foundation (IOF) on FRAX®: Executive Summary of the 2010 Position Development Conference on Interpretation and Use of FRAX® in Clinical Practice. J Clin Densitom 2011;14(3):171-80. The joint Official Positions of the ISCD and IOF are the most updated and accepted guidelines for quantitatively or qualitatively adjusting FRAX CRFs and subsequent fracture probabilities for the individual patient.
34. Kanis J, Hans D, Cooper C, et al. Interpretation and use of FRAX® in clinical practice. Osteoporos Int 2011;22(9):2395-411. The joint Official Positions of the ISCD and IOF are the most updated and accepted guidelines for quantitatively or qualitatively adjusting FRAX CRFs and subsequent fracture probabilities for the individual patient.
35. FRAX available at http://www.shef.ac.uk//FRAX, accessed February 23, 2011.
36. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-46. (Pubitemid 47020000)
37. Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237-44. (Pubitemid 34680500)
38. Cooper C, Cole ZA, Holroyd CR, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22(5):1277-88.
39. Leslie WD, Lix LM. Effects of FRAX® model calibration on intervention rates: a simulation study. J Clin Densitom. 2011;14(3):272-8.
40. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. Springer (New York); 2008.
41. Leslie WD, Lix LM, Langsetmo L, et al. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 2011;22:817-27. This describes the creation of a FRAX model for fracture assessment in Canadian men and women.
42. Leslie WD, Lix LM, Johansson H, et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010;25(11):2350-8.
43. Fraser L-A, Langsetmo L, Berger C, et al. Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos. Osteoporos Int. 2011;22:829-37.
44. FRAX Implementation Guide available at http://www.nof.org/ sites/default/files/pdfs/nof-FRAX-Implem-Guide.pdf, accessed February 24, 2011.
45. FRAX Implementation Guide available at http://www.iscd.org/ visitors/pdfs/FRAXimplementationGuide-000.pfd, accessed February 24, 2011.
46. Watts NB, Siris ES, Cummings SR, Bauer DC. Perspective: Filtering FRAX®. Osteoporos Int. 2010;21:537-41.
47. McCloskey E, Compston J, Cooper C. The US FRAX® filter: avoiding confusion or hindering progress? Osteoporos Int. 2010;21:885.
48. National Osteoporosis Guideline Group (NOGG). Osteoporosis: clinical guidelines for prevention and treatment Executive Summary. 2010. The UK NOGG assessment and diagnosis of osteoporosis and therapeutic agents available for treatment provides different management strategies for the prevention and treatment of osteoporotic fractures in postmenopausal women and men over 50 years of age.
49. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-97.
50. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408. The use of a case-finding strategy for the management of osteoporosis with FRAX reviews the use of FRAX as a screening tool with and without bone density testing for the treatment of osteoporosis in the United Kingdom.
51. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009;24:675-80.
52. Dawson-Hughes B, Looker AC, Tosteson AN, et al. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int. 2010;21(1):41-52.
53. Papaioannou A, Morin S, Cheung AM, et al. for the Scientific Advisory Council of Osteoporosis Canada. 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Can Med Assoc J 2010;182(17):1864-73. The Canadian Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada reviews the use of the FRAX model in Canada in contrast to US and UK Osteoporosis Guidelines.
54. Leslie WD, Berger C, Langsetmo L, Adachi JD, et al. CaMos Research Group. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba BMD cohorts. Osteoporos Int. 2011;22:1873-83.
55. Leslie WD, Morin S. Fracture burden in relation to low bone mineral density and FRAX® probability. J Clin Densitom. 2011;14(3):279-85.
56. Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporosis International 2011; August 18 [Epub ahead of print].
57. Preventive Services US. Task Force. Screening for osteoporosis: U.S.Preventive services task force recommendation statement. Ann Intern Med. 2011;154(5):356-64.
58. Kanis JA, McCloskey E, Johansson H, et al. FRAX® with and without BMD. Calcified Tissue International 2011; [Epub ahead of print].
59. Leslie WD, Morin S. Fracture burden in relation to low bone mineral density and FRAX® probability. J Clin Densitom. 2011;14(3):279-85.
60. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. A comparative study of using non hip bone density inputs with FRAX®. Osteoporos Int 2011;Oct 19. [Epub ahead of print].
61. Gillespie LD, Robertson MC, Lamb SE, et al. 2010 Interventions for preventing falls in older people living in the community (Review); The Cochrane Collaboration; available at http://onlinelibrary.wiley.com/o/cochrane/clsysrev/ articles/CD007146/frame.html, accessed February 24, 2011.
62. Cameron ID, Murray GR, Gillespie LD, et al. 2010 Interventions for preventing falls in older people in nursing care facilities and hospitals (Review); available at http://onlinelibrary.wiley.com/o/ cochrane/clsysrev/ articles/CD005465/frame.html, accessed February 25, 2011.
63. Howe TE, Rochester L, Jackson A. 2008 Exercise for improving balance in older people (Review); available at http://onlinelibrary.wiley.com/o/cochrane/ clsysrev/articles/CD004963/frame.html, accessed February 25, 2011.
64. Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809-16.
65. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515-26.
66. Kanis article above, van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology: (Oxford) 2000;39:1383-89. (Pubitemid 32045866)
67. ReidDM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res. 2000;15 (6):1006-13. (Pubitemid 30350063)
68. Michel BA, Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. The J of Rheum. 1993;20(10):1666-9. (Pubitemid 24017566)
69. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J of Endocrin. 1997;137:209-17.
70. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Annals of the Rheum Dis. 1995;54:49-52.
71. De Vries F, Brache M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208-14. (Pubitemid 46106193)
72. Johnell O, Kanis JA, Oden A, Johansson H, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185-94. (Pubitemid 40863806)
73. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42:467-75.
74. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468-89. (Pubitemid 28486716)
75. Jones G, Nguyen T, Sambrook PN, Kelly PJ, et al. A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol. 1995;22:932-6.
76. Phillipov G, Phillips PJ. Skeletal site bone mineral density heterogeneity in women and men. Osteoporos Int. 2001;12:362-5. (Pubitemid 32606459)
77. Schneider DL, Bettencourt R, Barrett-Connor E. Clinical utility of spine bone density in elderly women. J Clin Densitom. 2006;9:255-60. (Pubitemid 44247799)
78. Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom. 1999;2:343-50.
79. Leslie WD, Lix LM, Tsang JF, et al. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med 2007;1641-47. (Pubitemid 47280345)
80. Leslie WD, Lix LM. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. J Bone Miner Res. 2011;26:460-7.
81. Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int. 2011;22:839-47.
82. Leslie WD, Kovacs CS, Olszynski WP, et al. Spine-Hip T-score difference predicts major osteoporositic fracture risk independent of FRAX®: a population-based report from CAMOS. J Clin Densitom. 2011;14(3):286-93.